Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235109 | 0.94 | MGAM (0.39) | MGAMMAPTNR1H2NR1H3ESR1 | |
| SCHEMBL28024246 | 0.86 | MAPT (0.41) | MGAMMAPTNR1H2NR1H3ESR1 | |
| SCHEMBL18084487 | 0.86 | MGAM (0.44) | MGAMMAPTNR1H2NR1H3ESR1 | |
| SCHEMBL3238058 | 0.83 | ESR1 (0.34) | MGAMMAPTESR1ESR2SLC9A1 | |
| SCHEMBL9217667 | 0.81 | MAPT (0.47) | MGAMMAPTNR1H2NR1H3ESR1 | |
| SCHEMBL8908096 | 0.81 | ESR1 (0.33) | MGAMMAPTESR1ESR2SLC9A1 | |
| SCHEMBL9633376 | 0.81 | NR1H2 (0.39) | MGAMNR1H2NR1H3 | |
| SCHEMBL5801979 | 0.80 | NR1H2 (0.53) | MGAMMAPTNR1H2NR1H3ESR1 | |
| SCHEMBL4271660 | 0.80 | SLC9A1 (0.32) | SLC9A1KCNA3 | |
| Methane SCHEMBL27264866 | 0.79 | NR1H2 (0.38) | MGAMNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069330-A1 | Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors | Gately, Stephen (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008147814-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARING AND USING LIPOPHILIC ORGANOSULFUR CELL PROLIFERATION INHIBITORS | SILAMED, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-5536732-A | REDUCING INFECTIOUSNESS OF HIV | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0454580-B1 | Novel nojirimycin derivatives | MERRELL DOW PHARMA (US) | 1995-12-27 | — | — | EP | disclosed |
| US-5252587-A | Viricides, aids therapy, antidiabetic agent | MERRELL DOW PHARMACEUTICALS, INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0454580-A2 | Novel nojirimycin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-30 | — | — | EP | disclosed |
| EP-0453692-A1 | Novel nojirimycin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069330-A1 | Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors | SI, SLCO2B1, SLCO1B1 | MGAM 1271/4885MAPT 2080/4885NR1H2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.